Shinji Tamada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shinji Tamada has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Wataru Obara
Department of Urology Iwate Medical University School of Medicine Iwate Japan
3 shared publications - Daiki Ikarashi
Department of Urology, Iwate Medical University School of Medicine, Iwate, Japan
2 shared publications Hiromitsu Fujisawa
Department of Urology Iwate Prefectural Central Hospital 4‐1 Morioka‐shi Iwate Japan
1 shared publicationJun Sugimura
Department of Urology, Iwate Medical University , Iwate , Japan
1 shared publicationKazuhiro Iwasaki
Department of Urology Iwate Prefectural Central Hospital 4‐1 Morioka‐shi Iwate Japan
1 shared publicationKazumasa Isurugi
Department of Urology Iwate Prefectural Central Hospital 4‐1 Morioka‐shi Iwate Japan
1 shared publication
Latest Publications
- Open Access
- 6 April 2026
- Published by Elsevier in SSRN Electronic Journal
Financial burden of immune checkpoint inhibitor maintenance therapy in Japan: a real-world cost analysis from an academic medical center
Background: Immune checkpoint inhibitors (ICIs) have transformed cancer care, but have also imposed substantial financial pressure on publicly funded healthcare systems. In clinical practice, ICI maintenance therapy (MT) is often continued for prolonged periods in patients without disease progression. However, analyses of the economic structure of ICI-MT remain limited.Methods: We retrospectively analyzed medical records of patients who received outpatient drug therapy for 16 types of cancer at Iwate Medical University Hospital during the 2022 fiscal year. MT was defined as any single regimen therapy lasting 13 or more months.Results: A total of 1,425 patients underwent 178 therapeutic regimens across 8,179 treatment opportunities, with annual costs totaling ~2.5 billion JPY. ICI regimens were significantly more expensive than other approaches. ICI monotherapy was the most common and accounted for 44% of total drug expenditure. ICI-MT was administered to 47 patients (3%), which accounted for 473 treatment opportunities (6%). Despite its limited use, ICI-MT represented 11% of total expenditure (272 million JPY), which accounted for the largest fraction of MT cost at 64%. Conclusion: ICI-MT was given to only 3% of patients, but accounted for 11% or more of total expenditure, identifying prolonged ICI-MT as a concentrated driver of drug expenditures and financial burden in cancer care. These findings highlight the need for optimized treatment duration strategies in routine oncology practice, potentially supported by biomarker approaches such as circulating tumor DNA.
- 6 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessFinancial burden of immune checkpoint inhibitor maintenance therapy in Japan: a real-world cost analysis from an academic medical center
Background: Immune checkpoint inhibitors (ICIs) have transformed cancer care, but have also imposed substantial financial pressure on publicly funded healthcare systems. In clinical practice, ICI maintenance therapy (MT) is often continued for prolonged periods in patients without disease progression. However, analyses of the economic structure of ICI-MT remain limited.Methods: We retrospectively analyzed medical records of patients who received outpatient drug therapy for 16 types of cancer at Iwate Medical University Hospital during the 2022 fiscal year. MT was defined as any single regimen therapy lasting 13 or more months.Results: A total of 1,425 patients underwent 178 therapeutic regimens across 8,179 treatment opportunities, with annual costs totaling ~2.5 billion JPY. ICI regimens were significantly more expensive than other approaches. ICI monotherapy was the most common and accounted for 44% of total drug expenditure. ICI-MT was administered to 47 patients (3%), which accounted for 473 treatment opportunities (6%). Despite its limited use, ICI-MT represented 11% of total expenditure (272 million JPY), which accounted for the largest fraction of MT cost at 64%. Conclusion: ICI-MT was given to only 3% of patients, but accounted for 11% or more of total expenditure, identifying prolonged ICI-MT as a concentrated driver of drug expenditures and financial burden in cancer care. These findings highlight the need for optimized treatment duration strategies in routine oncology practice, potentially supported by biomarker approaches such as circulating tumor DNA.
- 29 December 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (4) , 489-497
Prevalence of germline BRCA1/2 pathogenic variants in Japanese patients treated with castration-resistant prostate cancer and efficacy of CRPC treatment in real-world clinical practice
The companion diagnosis for olaparib, a poly (ADP-ribose) polymerase inhibitor for prostate cancer, aims to detect BRCA1/2 gene variants. In clinical practice, the frequency of germline BRCA1/2 variants in patients receiving castration-resistant prostate cancer treatment is unknown. We aimed to evaluate the prevalence of germline BRCA1/2 variants and their relationship to prognosis and treatment efficacy in castration-resistant prostate cancer. Between June 2021 and 2023, 92 patients receiving castration-resistant prostate cancer treatment were examined for germline BRCA1/2 variants using BRACAnalysis CDx®. Furthermore, the associations between BRCA1/2 pathogenic variants and clinical outcomes were assessed. Of the 92 patients referred for genetic testing, 6 (6.5%) carried germline pathogenic variants in BRCA1/2. The BRCA2 variant was the most frequent (n = 5), followed by BRCA1 variant (n = 1). Among the five variants in BRCA2, the p.Asp427Thrfs*3 variant was identified for the first time in prostate cancer. Overall survival from castration-resistant prostate cancer for patients with BRCA1/2 variants was significantly shorter than for patients without BRCA1/2 variants (P = 0.043). Progression-free survival of androgen receptor signaling inhibitors for patients with BRCA1/2 variants was significantly shorter than for those without (P = 0.003). Progression-free survival of taxane chemotherapy was significantly shorter in patients with BRCA1/2 variants than in those without (P = 0.0149). In clinical practice, 6.5% of patients treated with castration-resistant prostate cancer carried germline BRCA1/2 pathogenic variants. Japanese castration-resistant prostate cancer patients with germline BRCA1/2 mutants have a poor prognosis and may be less responsive to treatment with androgen receptor signaling inhibitors and taxane-based chemotherapy for castration-resistant prostate cancer.
- 29 December 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (4) , 489-497
Prevalence of germline BRCA1/2 pathogenic variants in Japanese patients treated with castration-resistant prostate cancer and efficacy of CRPC treatment in real-world clinical practice
The companion diagnosis for olaparib, a poly (ADP-ribose) polymerase inhibitor for prostate cancer, aims to detect BRCA1/2 gene variants. In clinical practice, the frequency of germline BRCA1/2 variants in patients receiving castration-resistant prostate cancer treatment is unknown. We aimed to evaluate the prevalence of germline BRCA1/2 variants and their relationship to prognosis and treatment efficacy in castration-resistant prostate cancer. Between June 2021 and 2023, 92 patients receiving castration-resistant prostate cancer treatment were examined for germline BRCA1/2 variants using BRACAnalysis CDx®. Furthermore, the associations between BRCA1/2 pathogenic variants and clinical outcomes were assessed. Of the 92 patients referred for genetic testing, 6 (6.5%) carried germline pathogenic variants in BRCA1/2. The BRCA2 variant was the most frequent (n = 5), followed by BRCA1 variant (n = 1). Among the five variants in BRCA2, the p.Asp427Thrfs*3 variant was identified for the first time in prostate cancer. Overall survival from castration-resistant prostate cancer for patients with BRCA1/2 variants was significantly shorter than for patients without BRCA1/2 variants (P = 0.043). Progression-free survival of androgen receptor signaling inhibitors for patients with BRCA1/2 variants was significantly shorter than for those without (P = 0.003). Progression-free survival of taxane chemotherapy was significantly shorter in patients with BRCA1/2 variants than in those without (P = 0.0149). In clinical practice, 6.5% of patients treated with castration-resistant prostate cancer carried germline BRCA1/2 pathogenic variants. Japanese castration-resistant prostate cancer patients with germline BRCA1/2 mutants have a poor prognosis and may be less responsive to treatment with androgen receptor signaling inhibitors and taxane-based chemotherapy for castration-resistant prostate cancer.
- Open Access
- 26 September 2022
- Published by Wiley in IJU Case Reports
- Vol. 5 (6) , 438-441
Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases
Introduction: Immunotherapy‐based combinations have become the standard first‐line therapy for metastatic renal cell carcinoma. However, combined immunotherapy for renal collecting duct carcinoma had been reported, but its therapeutic efficacy had been unclear.Case presentation: The first case was a 62‐year‐old man treated with pembrolizumab and axitinib for renal collecting duct carcinoma with multiple bone metastases. After 7 months, the primary and metastatic lesions shrunk and were evaluated as a partial response. The second case was a 71‐year‐old man treated with pembrolizumab and axitinib for renal collecting duct carcinoma with lymph node and lung metastases. After 9 months, the primary and metastatic lesions shrunk and were evaluated as a partial response. In both cases, the tumor cell expression of programmed death ligand‐1 was negative, and CD4+ and CD8+ cells were observed in the tumor.Conclusion: Combined immunotherapy with pembrolizumab and axitinib may be effective for metastatic renal collecting duct carcinoma.
- 26 September 2022
- Published by Wiley in IJU Case Reports
- Vol. 5 (6) , 438-441
Open AccessEfficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases
Introduction: Immunotherapy‐based combinations have become the standard first‐line therapy for metastatic renal cell carcinoma. However, combined immunotherapy for renal collecting duct carcinoma had been reported, but its therapeutic efficacy had been unclear.Case presentation: The first case was a 62‐year‐old man treated with pembrolizumab and axitinib for renal collecting duct carcinoma with multiple bone metastases. After 7 months, the primary and metastatic lesions shrunk and were evaluated as a partial response. The second case was a 71‐year‐old man treated with pembrolizumab and axitinib for renal collecting duct carcinoma with lymph node and lung metastases. After 9 months, the primary and metastatic lesions shrunk and were evaluated as a partial response. In both cases, the tumor cell expression of programmed death ligand‐1 was negative, and CD4+ and CD8+ cells were observed in the tumor.Conclusion: Combined immunotherapy with pembrolizumab and axitinib may be effective for metastatic renal collecting duct carcinoma.